1
Clinical Trials associated with Monovalent mRNA NA Vaccine(Sanofi Pasteur)Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM injection in healthy adults aged 18 years and older. Two age groups, 18 to 64 years and ≥65 years, will be included in this study.
100 Clinical Results associated with Monovalent mRNA NA Vaccine(Sanofi Pasteur)
100 Translational Medicine associated with Monovalent mRNA NA Vaccine(Sanofi Pasteur)
100 Patents (Medical) associated with Monovalent mRNA NA Vaccine(Sanofi Pasteur)
100 Deals associated with Monovalent mRNA NA Vaccine(Sanofi Pasteur)